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ABSTRACT
Background    Nonalcoholic fatty liver disease/steato-
hepatitis (NAFLD/NASH) is a chronic liver disease 
related to metabolic syndrome that can progress to 
liver cirrhosis. The involvement of the endoplasmic 
reticulum (ER) stress response in NAFLD progression 
and the roles played by activating factor 3 (ATF3) and 
the downstream nuclear protein 1 (NUPR1) are poorly 
understood. The aim of this study was to determine the 
gene expression profiles around the ATF3/NUPR1 axis 
in relation to the development of NAFLD using novel 
mouse models.
Methods    Fatty liver Shionogi (FLS) mice (n = 12) 
as a NAFLD model and FLS-ob/ob mice (n = 28) as a 
NASH model were fed a standard diet. The FLS mice 
were sacrificed at 24 weeks of age as a control, whereas 
the FLS-ob/ob mice were sacrificed at 24, 36, and 48 
weeks of age. Hepatic steatosis, inflammation, and 
fibrosis were evaluated by biochemical, histological, 
and gene expression analyses. The expression levels of 
the ER-stress related genes Jun proto-oncogene (C-jun), 
Atf3, Nupr1, and C/EBP homologous protein (Chop) 
were measured in liver tissue. Apoptosis was evaluated 
by terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) staining.
Results    Control mice demonstrated hepatic steatosis 
alone without apparent fibrosis. On the other hand, FLS-
ob/ob mice showed severe steatohepatitis at both 24 and 
36 weeks of age and severe fibrosis at both 36 and 48 
weeks of age. The expression levels of Atf3, Nupr-1, and 
C-jun significantly increased from 24 to 48 weeks of age 
in FLS-ob/ob mice compared with control mice. The 
expression level of Chop was already high in FLS mice 
and maintained similar levels in FLS-ob/ob mice; the 
expression level was consistent with the percentage of 
TUNEL-positive cells.
Conclusion    The ATF3/NUPR1 axis plays a pivotal 
role in NASH progression in association with C-jun and 
Chop and appears to induce apoptosis from early steato-
sis in the NASH model mice.
Key words    endoplasmic reticulum stress; mouse 
model; nonalcoholic fatty liver disease; nonalcoholic 
steatohepatitis 
Nonalcoholic fatty liver disease (NAFLD) has emerged 
as a common public health problem in recent decades. 
The prevalence of NAFLD ranges from 30% to 46% in 
Western countries1 and is increasing in the Asia-Pacific 
region.2 Although the underlying mechanisms leading 
to the development of NAFLD have been discovered 
through the efforts of researchers, they are not fully 
understood.3, 4
 The mechanism of endoplasmic reticulum (ER) 
stress was unveiled by Kazutoshi Mori and Peter Walter 
in the 1990s.5, 6 ER stress is activated to regulate protein 
synthesis and restore homeostatic equilibrium when the 
cell is stressed due to the accumulation of unfolded or 
misfolded proteins. However, delayed or insufficient re-
sponses to ER stress turn physiological mechanisms into 
pathological consequences, including fat accumulation, 
insulin resistance, inflammation, and apoptosis. Through 
their remarkable contributions to this field, many re-
searchers have elucidated that ER stress induces various 
types of diseases.7 Some studies have also demonstrated 
that obesity induces ER stress and that ER stress plays 
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a pivotal role in both the development of steatosis and 
the progression to steatohepatitis.8, 9 Therefore, under-
standing of the role of ER stress in the pathogenesis of 
NAFLD has become a topic of intense investigation.10
 Under a chronic imbalance between energy supply 
and demand in fatty liver, toxic lipids activate cellular 
stress pathways. The accumulation of unfolded or mis-
folded proteins in the ER usually triggers an adaptive 
response aimed at resolving ER stress, the unfolded pro-
tein response (UPR). The UPR is mediated by at least 
three different stress-sensing pathways, including pan-
creatic ER kinase (PERK), inositol-requiring enzyme 1, 
and activating transcription factor 6 (ATF6).11
 Among the ATF family members, ATF4 is down-
stream of PERK and eukaryotic initiation factor 2 
alpha.12 ATF3 is also a downstream target of ATF4 and 
acts as a hub of the cellular adaptive-response network.13 
ATF4 activates the transcription factor nuclear protein 
1 (NUPR1) (also known as p8/Com-1), which regulates 
the expression of metabolic stress-responsive genes, 
especially those involved in DNA repair and cell cycle 
regulation.14 Previous studies have indicated that ATF3 
is highly expressed when the cells are exposed to stress 
signals.13, 15 NUPR1 is also considered one of the down-
stream genes of ATF3.16 The encoding gene, Nupr1, is 
overexpressed in the liver of NAFLD model mice on 
microarray analysis.17 However, the role of the ATF3/
NUPR1 axis in NFLD progression is not known.
 We have previously reported that the fatty liver 
Shionogi (FLS) mouse and FLS-ob/ob mouse are good 
models for NASH study.18 FLS mice show hypertri-
glyceridemia from birth and develop chronic fatty 
liver (hepatic steatosis) without obesity under normal 
conditions. The hypertriglyceridemia and the fatty liver 
in the FLS mice is assumed to be caused by a decreased 
level of Apo-CII and increased level of Apo-CIII in 
plasma.19 In addition, FLS-ob/ob mice show hyperpha-
gia, obesity, hyperlipidemia, and diabetes mellitus and 
have histologically proven severe liver steatosis and 
fibrosis. Interestingly, FLS mice and FLS-ob/ob mice 
also develop liver cancer at 36 and 48 weeks of age.18, 20 
NUPR1 has been reported to be related to liver cancer as 
well.21, 22 Determination of the role of NUPR1 in NAFLD 
progression could additionally shed light on carcinogene-
sis in NASH. For these reasons, we focused on the role of 
the ATF3/NUPR1 axis in ER stress.
 In this study, we aimed to determine the gene ex-
pression profiles around the ATF3/NUPR1 axis during 
the development of NAFLD using these novel mouse 
NAFLD/NASH models.
MATERIALS AND METHODS
Animals
Male FLS (n = 12) and FLS-ob/ob (n = 28) mice were 
obtained from Shionogi Research Laboratories (Shiga, 
Japan). The animals were housed in a room maintained 
at a controlled temperature of 24 ± 2 °C under a 12-h 
light-dark cycle. Animals were allowed ad libitum 
access to standard pellet chow and water. All experi-
ments were carried out in accordance with the Animal 
Experimentation Guidelines of Tottori University. At 
24, 36, and 48 weeks, the animals were killed under 
pentobarbital anesthesia and blood was collected from 
the right ventricle. The animal numbers in the various 
experimental groups were as follows: 12 in the 24-week-
old FLS mouse group, 9 in the 24-week-old FLS-ob/ob 
mouse group, 10 in the 36-week-old FLS-ob/ob mouse 
group, and 9 in the 48-week-old FLS-ob/ob mouse 
group. FLS mice of the 24-week-old group were defined 
as the control simple steatosis model. Plasma samples 
were frozen and stored at –80 °C. The liver and visceral 
fat were also collected, weighed, immediately frozen in 
liquid nitrogen, and stored at –80 °C. Liver specimens 
were fixed in 10% buffered formalin and embedded in 
paraffin for histological analysis.
Biochemical analyses
Blood samples were immediately separated via cen-
trifugation at 2000 × g for 15 min and stored at –80 °C 
until further assay. Serum samples were analyzed to 
determine the levels of alanine aminotransferase (ALT), 
triglyceride (TG), and total cholesterol.
Histological analysis
Sections (4 μm thick) of formalin-fixed, paraffin-
embedded liver were stained with Sirius red and hema-
toxylin and eosin. The areas of hepatic fibrosis and of 
lipid droplets were measured in five randomly selected 
fields/section (magnification ×100) for each specimen 
using Win ROOF version 5.71 (Mitsutani Co., Tokyo, 
Japan).
Terminal deoxynucleotidyl transferase dUTP nick 
end labeling staining
A fluorescent terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL) assay (In Situ Cell 
Death Detection Kit; Roche, Basel, Switzerland) was 
used on tissue sections. Sections were paraformaldehyde-
fixed and hydrated. We randomly selected five repre-
sentative slides from each group. The TUNEL assay 
was then performed according to the manufacturer’s 
protocol. Staining for negative controls was performed 
without enzyme on the slides of control mice and FLS-
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ob/ob mice at 24 weeks of age. Slides were mounted 
with ProLong Antifade (Invitrogen–Molecular Probes, 
Carlsbad, CA) containing 4’,6-diamidino-2-phenylindole 
(DAPI). The slides were analyzed using a fluorescent 
microscope (BZ-X710; Keyence, Osaka, Japan). Dead 
cells were quantified by counting TUNEL-positive nu-
clei in 10 random microscopic fields (×20).
Hepatic cholesterol content analysis
Snap-frozen liver (50 mg) was homogenized and ex-
tracted using a chloroform-methanol (2:1 v/v) mixture. 
Then, the organic phase was dried and solubilized in 
2-propanol containing 10% Triton X-100. Total choles-
terol was determined using commercial enzymatic kits 
(Cholesterol E-test; Wako Pure Chemical Industries, 
Osaka, Japan).
RNA extraction and reverse transcription
Tissue samples were homogenized, and total RNA was 
extracted using an RNeasy Mini Kit (Qiagen, Hilden, 
Germany). RNA concentration was determined by the 
absorbance at 260 nm, and the RNA quality was verified 
by electrophoresis on ethidium bromide-stained 1% aga-
rose gels. Total RNA (~2 μg) was then reverse-transcribed 
in a final volume of 11.5 μL containing 4 μL of 5× 
standard buffer, 2 μL of 0.1 M dithiothreitol, 1 μL of 
SuperScript II RNase H reverse transcriptase (Invitrogen), 
2 μL of 10 M dNTPs (Promega, Madison, WI), 1 μL of 
50 pmol/μL Random Primer (Promega), 0.5 μL of 100 
pmol/μL Oligo (dt)15 Primer (Promega), and 1 μL of 
40 U/μL ribonuclease inhibitor (Wako Pure Chemical 
Industries). Samples were then incubated at 37 °C for 60 
min and 95 °C for 5 min and cooled to 4 °C for 5 min.
Table 1. The primer lists used for Real time PCR
Primer sequence (5’–3’)
Gene GenBank Accession no. Forward Reverse
Tgfb1 NM_011577 TGGAGCAACATGTGGAACTC GTCAGCAGCCGGTTACCA
Col1a1 NM_007742 ACCTAAGGGTACCGCTGGA TCCAGCTTCT CCATCTTTGC
Timp1 NM_001044384 GCAAAGAGCTTTCTCAAAGACC AGGGATAGATAAACAGGGAAACACT
Tnfa NM_013693 CTGTAGCCCACGTCGTAGC TTGAGATCCATGCCGTTG
Srebp1 NM_011480 TCAAGCAGGAGAACCTGACC TCATGCCCTCCATAGACACA
Ppara NM_011144 CTGAGACCCTCGGGGAAC AAACGTCAGTTCACAGGGAAG
C-jun NM_010591 CCAGAAGATGGTGTGGTGTTT CTGACCCTCTCCCCTTGC
Atf3 NM_007498 GCAAAGCAGGATCCCACTAAT CCACCCCACCTATCAAGGTA
Nupr1 NM_019738 GAAGCTGCTGACCAAGTTCC GTGTGGTGTCTGTGGTCTGG
Chop NM_007837 GCGACAGAGCCAGAATAACA GATGCACTTCCTTCTGGAACA
β-actin NM_007393 GGATGCAGAAGGAGATTACTGC CCACCGATCCACACAGAGTA
Atf3, activating factor 3; Chop, C/EBP homologous protein; C-jun, jun proto-oncogene; Col1a1, collagen pro-alpha-1 type I chain; Nupr1, 
nuclear protein transcription regulator 1; Ppara, peroxisome proliferator-activated receptor-alpha; Srebp1, sterol regulatory element bind-
ing protein 1; Tgfb1, transforming growth factor beta 1; Timp1, tissue inhibitor of metalloproteinases-1; Tnfa, tumor necrosis factor-alpha.
Table 2. Physiological and biochemical parameters in the all groups
FLS-ob/ob
Control (n = 12) 24 W (n = 9) 36 W (n = 10) 48 W (n = 9)
Body weight (g) 44.28 ± 2.58** 58.92 ± 3.84*†† ‡‡ 66.25 ± 2.96*** 70.24 ± 5.24 ***
Liver weight (g) 2.68 ± 0.56** 7.88 ± 1.23* 9.02 ± 1.52*‡‡ 7.15 ± 1.65 *††
LW (g)/BW (g) 0.075 ± 0.01** 0.133 ± 0.015*‡‡ 0.136 ± 0.019 *‡‡ 0.101 ± 0.02***††
Fat weight (g) 1.42 ± 0.09** 2.28 ± 0.23*†† ‡‡ 1.98 ± 0.17*‡‡ 1.67 ± 0.34***††
Serum TG (mg/g) 166.08 ± 46.98 195.56 ± 59.55 192.60 ± 39.54‡‡ 161.63 ± 25.03††
Serum chol (mg/g) 114.58 ± 25.65** 300.22 ± 35.63*†† ‡‡ 248.50 ± 38.08*‡‡ 193.50 ± 37.09***††
Serum ALT (IU/L) 71.58 ± 48.75** 290.25±115.61* 226.10 ± 51.42* 227.25 ± 48.66*
Liver TG (mg/g) 353.05 ± 67.72**‡‡ 425.93 ± 125.41*†† ‡‡ 371.38 ± 46.38**‡‡ 250.44 ± 72.02**††
Liver chol (mg/g) 119.49 ± 25.82 111.08 ± 36.54 138.04 ± 32.53 114.63 ± 30.49
Data are expressed as the mean ± standard deviation. *P < 0.05 vs 24-week-old FLS mice, **P < 0.05 vs 24-week-old FLS-ob/ob mice, 
††P < 0.05 vs 36-week-old FLS-ob/ob mice, ‡‡P < 0.05 vs 48-week-old FLS-ob/ob mice. ALT, alanine aminotransferase; BW, body 
weight; chol, cholesterol; FLS, fatty liver Shionogi; LW, liver weight; TG, triglyceride; W, weeks. 
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Quantitative polymerase chain reaction
Quantitative polymerase chain reaction (PCR) was 
performed in a final volume of 10 mL containing 250 
nM of universal Probe Library probe (Roche), 900 
nM of forward primer, 900 nM of reverse primer, 5 
mL of EXPRESS qPCR Supermix with Premixed 
Rox (Invitrogen), and 2 mL of cDNA. A real-time RT-
PCR analysis was performed with a 7900HT Fast Real-
Time PCR System with SDS2.3 software (Applied 
Biosystems, Carlsbad, CA). Thermal cycle conditions 
were as follows: hold at 95 °C for 20 s, then 45 repeated 
cycles of 95 °C for 1 s and 60 °C for 20. All results were 
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Fig. 1. Histological analysis. Hematoxylin and eosin (H&E) staining was used to analyze the area of lipid droplets as vacuoles. Sirius 
red staining was used to analyze the area of fibrosis. (A) Control liver stained with H&E; (B) 24-week-old FLS-ob/ob liver stained with 
H&E; (C) 36-week-old FLS-ob/ob liver stained with H&E; (D) 48-week-old FLS-ob/ob liver stained with H&E; (E) the ratio of the 
lipid droplet area; (F) control liver stained with Sirius red; (G) 24-week-old FLS-ob/ob liver stained with Sirius red; (H) 36-week-old 
FLS-ob/ob liver stained with Sirius red; (I) 48-week-old FLS-ob/ob liver stained with Sirius red; (J) the ratio of the fibrosis area. *P < 0.05 
compared with control, †P < 0.05 compared with 24-week-old FLS-ob/ob mice. CNT, control mice; FLS, fatty liver shionogi; W, weeks. 
Scale bar = 100 μm.
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Fig. 2. Hepatic gene expression levels of Tnfa, Tgfb1, Col1a1, and Timp-1 in FLS mice and FLS-ob/ob mice. (A) Gene expression of 
Tnfa; (B) gene expression of Tgfb1, (C) gene expression of Col1a1; (D) gene expression of Timp-1. *P < 0.05 compared with control, †P < 0.05 
compared with 24-week-old FLS-ob/ob mice. CNT, control mice; Col1a1, collagen pro-alpha-1 type I chain; FLS, fatty liver shionogi; 
Tgfb1, transforming growth factor beta 1; Timp-1, tissue inhibitor of metalloproteinases-1; Tnfa, tumor necrosis factor-alpha; W, weeks.
standardized to the levels of β-actin. The primers used 
for PCR were listed in Table 1. 
Statistical analysis
The Mann-Whitney test was used to assess the statistical 
significance of differences between two groups. All 
statistical tests were performed using StatFlex (Windows 
ver. 6.0; Artech, Osaka, Japan). All values are expressed 
as the mean ± standard deviation. Values of P less than 
0.05 were considered significant.
RESULTS
FLS-ob/ob mice mimic the human NASH pheno-
type
FLS-ob/ob mice gained body weight between 24 and 
48 weeks of age (from 59 ± 4 g to 70 ± 5 g). Liver, fat 
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Fig. 3. Hepatic gene expression levels of C-jun, Atf3, Nupr1, and Chop in FLS mice and FLS-ob/ob mice. (A) Gene expression of C-jun; (B) 
gene expression of Atf3; (C) gene expression of Nupr1; (D) gene expression of Chop. *P < 0.05 compared with control, †P < 0.05 compared 
with 24-week-old FLS-ob/ob mice. Atf3, activating transcription factor; Chop, C/EBP homologous protein; C-jun, jun proto-oncogene; 
CNT, control mice; FLS, fatty liver shionogi; n.s., not significant; Nupr1, nuclear protein-1; W, weeks.
weight, and the liver to body weight ratio also signifi-
cantly increased in the FLS-ob/ob mice compared with 
the FLS mice. These findings are consistent with the 
hepatic TG content but not with the cholesterol content. 
Serum ALT and cholesterol levels were also significant-
ly elevated in the FLS-ob/ob mice compared with the 
FLS mice. Serum cholesterol and TG levels were lower 
in FLS-ob/ob mice at 48 weeks of age than at 36 weeks 
of age (Table 2).
 Histological examinations of liver sections also demon-
strated significant steatosis at 24 and 36 weeks of age in the 
FLS-ob/ob mice compared with control mice (Figs. 1A–C). 
However, consistent with the serum lipid markers, steatosis 
was decreased at 48 weeks of age (Fig. 1D). The ratios of 
the lipid droplet areas in control, FLS-ob/ob mice at 24, 36, 
48 weeks of age were 19.9 ± 4.6%, 38.7 ± 5.9%, 37.7 ± 6.7% 
and 29.7 ± 9.9%, respectively (Fig. 1E). Sirius red staining 
revealed that hepatic fibrosis significantly and progressively 
increased over time in FLS-ob/ob mice compared with 
control mice (Figs. 1F–G). At 48 weeks of age, the liver 
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Fig. 4. TUNEL staining. Representative images of TUNEL staining in liver specimens from control and NASH model mice with 
quantifi cation of TUNEL-positive cells. (A) Negative control liver stained with TUNEL; (B) Negative control liver stained with DAPI; 
(C) Negative control FLS-ob/ob mice liver stained with TUNEL; (D) Negative control FLS-ob/ob mice liver stained with DAPI; (E) 
Control mice liver stained with TUNEL; (F) Control mice liver stained with DAPI; (G) 24-week-old FLS-ob/ob liver stained with 
TUNEL; (H) 4-week-old FLS-ob/ob liver stained with DAPI; (I) 36-week-old FLS-ob/ob liver stained with TUNEL; (J) 36-week-old 
FLS-ob/ob liver stained with DAPI; (K) 48-week-old FLS-ob/ob liver stained with TUNEL; (L) 48-week-old FLS-ob/ob liver stained 
with TUNEL; (M) The percentage of TUNEL-positive cells. *P < 0.05 compared with control, †P < 0.05 compared with 24-week-old 
FLS-ob/ob mice. CNT, control mice; DAPI, 4’,6-diamidino-2-phenylindole; FLS, fatty liver shionogi; NEG, negative control; TUNEL, 
terminal deoxynucleotidyl transferase dUTP nick end labeling; W, weeks. Scale bar = 50 μm.
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Fig. 6. Schematic of gene expression around the ATF3/NUPR1 axis. Excess toxic lipid induces inflammation through TNF-α, excessive ER 
stress is transduced through the ATF3 and NUPR-1 axis, and the excessive ER stress response ameliorates the protective effect of PPAR-α. 
For this reason, apoptosis and accelerated fibrosis are evident in the NASH mouse model. AP-1, activator protein-1; ATF, activating transcrip-
tion factor; Chop, C/EBP homologous protein; c-Jun, jun proto-oncogene; eIF2α, eukaryotic initiation factor 2α; ER, endoplasmic reticulum; 
JNK, c-Jun NH2-terminal kinase; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NUPR-1, nuclear protein-1; 
PERK, pancreatic ER kinase; PPAR-α, peroxisome proliferator-activated receptor-alpha; SREBP, sterol regulatory element binding protein; 
TGF-β1, transforming growth factor-β1; TIMP-1, tissue inhibitor of metalloproteinases-1; TNF-α, tumor necrosis factor-alpha.
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histology of the FLS-ob/ob mice showed cirrhosis (Fig. 1I). 
The area ratios of fibrosis in control, FLS-ob/ob mice at 
24, 36, 48 weeks of age were 2.5 ± 0.5%, 3.6 ± 0.9%, 8.5 ± 
3.4%, 10.2 ± 4.5%, respectively (Fig. 1J).
Inflammation- and fibrosis-associated gene ex-
pression is increased in the NASH model
The gene expression levels of tumor necrosis factor-
alpha (Tnfa) significantly increased at 24 and 48 weeks 
of age in FLS-ob/ob mice compared with control mice 
(Fig. 2A). In response to inflammatory signaling, the 
expression levels of transforming growth factor beta 1 
(Tgfb1) and collagen pro-alpha-1 type I chain (Col1a1), 
considered the strongest profibrogenic cytokines, and 
tissue inhibitor of metalloproteinases (Timp-1), which 
is related to the progression of fibrosis, also increased 
significantly and progressively at 24, 36, and 48 weeks 
compared with FLS mice (Figs. 2B–D).
Jun proto-oncogene (C-jun), Nupr1 and Atf3 ex-
pression increases according to NASH progres-
sion
C-jun expression also increased at 36 and 48 weeks of 
age in FLS-ob/ob mice (Fig. 3A). The expression levels 
of Nupr-1 and Atf3, which are ER stress-associated 
genes, were significantly increased at 24, 36 and 48 
weeks of age in FLS-ob/ob mice compared with control 
mice, respectively (Figs. 3B and C). The expression level 
of C/EBP homologous protein (Chop) was already high 
in the control mice and maintained the same expression 
levels in FLS-ob/ob mice (Fig. 3D).
Apoptosis appears from the early stage of NAFLD 
and persists in NASH mice
The percentage of TUNEL-positive cells divided by 
DAPI-positive cells was already high in control mice, 
and it remained at similar levels in FLS-ob/ob mice (Fig. 
4M). 
Lipid metabolism-associated genes are decreased 
in the NASH model
Peroxisome proliferator-activated receptor-alpha (Ppara) 
expression decreased at 24 and 48 weeks of age in the 
FLS-ob/ob mice (Fig. 5A). In addition, sterol regulatory 
element-binding transcription factor 1 (Srebp1) expres-
sion was significantly decreased in FLS-ob/ob mice only 
at 48 weeks of age (Fig. 5B).
DISCUSSION
In this study, we showed that the expression levels of 
genes participating in the ATF3/NUPR1 axis were 
progressively elevated and suggested to induce apoptosis 
from an early phase of steatosis in the NASH model 
mice.
 As we expected, FLS-ob/ob mice biochemically 
and histologically showed significant steatohepatitis and 
fibrosis compared with control mice. The gene expres-
sion of Tnfa significantly increased according to NASH 
progression. The proinflammatory cytokine TNF-α is 
considered an important mediator of insulin resistance 
in obesity.23 TNF-α activates the transcription of inflam-
matory genes via nuclear factor kappa B and activator 
protein-1 (AP-1) and also increases the expression of 
Tgfb1 and Timp1 in hepatocytes.24, 25 These results are 
also consistent with our findings.
 Atf3, Nupr1, and C-jun were highly expressed in 
our NASH model mice. A variety of subunits, includ-
ing c-Jun, ATF2, and ATF3, dimerize with AP-1.26 
Investigation of vascular endothelial cells has revealed 
that TNF-α-mediated induction of ATF3 mRNA is 
regulated by the c-Jun NH2-terminal kinase (JNK).27 
JNK regulates gene expression through the phosphor-
ylation and activation of a downstream transcription 
factor c-Jun. Research into systemic sclerosis showed 
that ATF3 plays a role in fibrosis through the regulation 
of TGF-β signaling.28 These gene expressions imply that 
TNF-α, ATF3, and c-Jun are closely linked and may 
dimerize with AP-1 and that they can also activate in-
flammatory and profibrotic gene transcription in NASH 
model mice.
 NUPR1, a small 82-amino acid polypeptide, was 
first described as a gene strongly induced in pancreatic 
acinar cells during the acute phase of pancreatitis.29 
It is involved in the stress response and in cancer pro-
gression.30 In the liver, NUPR1 has been shown to be 
an important element in the hepatocyte stress response 
after hepatic injury by CCl4.31 The authors indicated that 
the activation of NUPR1 allows rapid downregulation of 
CYP2E1 expression and consequently the extent of the 
liver injury. Therefore, NUPR1 seems to protect against 
such liver damage. However, its role in NAFLD/NASH 
is still not known. NUPR1 is also a positive feedback 
regulator of ATF4-dependent transcription.32 This means 
that NUPR1 additionally controls the target genes of 
ATF4, including CHOP. CHOP induces apoptosis as a 
component of the terminal UPR. In our study, the gene 
expression of Chop was already high in control mice and 
was at similar levels in NASH model mice. The TUNEL 
staining results seemed consistent with the Chop expres-
sion. Cells lacking ATF4 do not appear to express ATF3 
or CHOP.33 We can speculate that ATF4 which exists 
at the upstream is necessary for the expression of the 
ATF3/NUPR1 axis and CHOP, and that these proteins 
interact. The apoptotic signal induced by CHOP through 
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ATF4 in relation to the ATF3/NUPR1 axis seems to 
participate in the very early phase of NAFLD. However, 
another study using whole-body and tissue-specific 
ATF4-knockout mice demonstrated that ATF6 could 
also up-regulate CHOP expression independent of the 
PERK pathway.34 It remains a matter of speculation 
because we did not evaluate ATF6, but ATF6 might also 
be involved in Chop expression in such an early phase.
 In this study, we also analyzed the gene expression 
levels of the transcription factors involved in lipid metab-
olism regulation, Ppara and Srebp1. Ppara and Srebp1 
encode PPAR-α and sterol regulatory element-binding 
protein (SREBP)-1c, respectively. The expression levels 
of Ppara were significantly decreased in the NASH 
model. PPAR-α expression is enriched in hepatocytes, 
and it acts as a protective transcription factor in the 
liver, decreasing hepatocyte apoptosis in the acute liver 
failure mice model, particularly through the regula-
tion of ER stress.35 It is also considered a therapeutic 
target.36 Therefore, the suppression of PPAR-α by ER 
stress diminishes its protective effect and may promote 
NASH. On the other hand, ER stress induces cleavage of 
SREBP-1c and insulin resistance.37 Results from a previ-
ous human study suggest that hepatic overexpression of 
TNF-α is associated with downregulation of SREBP-1c 
and the development of burnt-out NASH.38 In the present 
study, the encoding gene Srebp1 was also significantly 
decreased in the NASH model. Additionally, it has been 
reported that Srebp1 levels are lower in FLS mice than 
in B6 mice at 48 weeks of age.39 Therefore, it can also be 
speculated that SREBP-1c plays a role in the early stage 
of NAFLD and not in NASH.
 Taking all gene expression results together, it is 
assumed that, in the early stage of NAFLD, excess toxic 
lipid generated by SREBP-1c induces inflammation 
through TNF-α and ER stress mediated through the 
ATF3 and NUPR-1 axis and that an excessive ER stress 
response ameliorates the protective effect of PPAR-α. 
This explains the apoptosis and accelerated fibrosis evi-
dent in the NASH mouse model (Fig. 6).
 Our study has two main limitations. First, we only 
evaluated gene expressions and therefore could not 
discuss the phosphorylation status of each protein asso-
ciated with the ATF3/NUPR1 axis. Second, we did not 
use a knockout system for Atf3 and Nupr1 and therefore 
could not precisely unravel the connection among each 
factor around the axis. Further study is necessary to 
determine the contribution of the ATF3/NUPR1 axis to 
NASH progression and carcinogenesis.
 In conclusion, we showed that the ATF3/NUPR1 
axis plays a pivotal role, in association with Tnfa, C-jun, 
Ppara, Srebp1, and Chop, in NASH progression.
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